AR068825A1 - Usos terapeuticos de antagonistas del receptor andrenergico alfa-1 - Google Patents

Usos terapeuticos de antagonistas del receptor andrenergico alfa-1

Info

Publication number
AR068825A1
AR068825A1 ARP080104131A ARP080104131A AR068825A1 AR 068825 A1 AR068825 A1 AR 068825A1 AR P080104131 A ARP080104131 A AR P080104131A AR P080104131 A ARP080104131 A AR P080104131A AR 068825 A1 AR068825 A1 AR 068825A1
Authority
AR
Argentina
Prior art keywords
andrenergic
alfa
antagonists
receiver
therapeutic uses
Prior art date
Application number
ARP080104131A
Other languages
English (en)
Inventor
Pierangelo Geppetti
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR068825A1 publication Critical patent/AR068825A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente proporciona el uso de un antagonista como Alfuzosina del receptor adrenérgico alfa-1 o sus sales farmacéuticamente aceptables para la preparacion de un medicamento para tratar y/o prevenir la cistitis intersticial, la vejiga sobreactiva y la sobreactividad del detrusor.
ARP080104131A 2007-09-26 2008-09-24 Usos terapeuticos de antagonistas del receptor andrenergico alfa-1 AR068825A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97532407P 2007-09-26 2007-09-26
EP07291148A EP2042179A1 (en) 2007-09-26 2007-09-26 Novel therapeutic uses of adrenergic alpha-1 receptor antagonists

Publications (1)

Publication Number Publication Date
AR068825A1 true AR068825A1 (es) 2009-12-09

Family

ID=38754714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104131A AR068825A1 (es) 2007-09-26 2008-09-24 Usos terapeuticos de antagonistas del receptor andrenergico alfa-1

Country Status (15)

Country Link
US (1) US8492396B2 (es)
EP (2) EP2042179A1 (es)
JP (1) JP5478495B2 (es)
AR (1) AR068825A1 (es)
AT (1) ATE524185T1 (es)
CY (1) CY1112203T1 (es)
DK (1) DK2203170T3 (es)
ES (1) ES2373354T3 (es)
HR (1) HRP20110919T1 (es)
ME (1) ME01259B (es)
PL (1) PL2203170T3 (es)
PT (1) PT2203170E (es)
RS (1) RS52069B (es)
SI (1) SI2203170T1 (es)
WO (1) WO2009040671A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020015377A1 (zh) * 2018-07-18 2020-01-23 温州医科大学 一种治疗近视的方法及制备药物的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
ATE327800T1 (de) * 1997-07-10 2006-06-15 Therakos Inc Behandlung von darm- oder blasenentzündungen
CA2434436A1 (en) * 2001-01-26 2002-08-01 Teddy Kosoglou Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002062389A1 (fr) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
CA2440141A1 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
AU2003260373B2 (en) * 2002-08-14 2008-02-21 Janssen Pharmaceutica N.V. Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
WO2005005395A2 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms

Also Published As

Publication number Publication date
WO2009040671A4 (en) 2009-05-28
JP5478495B2 (ja) 2014-04-23
US20110009436A1 (en) 2011-01-13
US8492396B2 (en) 2013-07-23
SI2203170T1 (sl) 2012-01-31
ES2373354T3 (es) 2012-02-02
WO2009040671A1 (en) 2009-04-02
RS52069B (en) 2012-06-30
EP2203170B1 (en) 2011-09-14
HRP20110919T1 (hr) 2012-01-31
ME01259B (me) 2013-06-20
PL2203170T3 (pl) 2012-02-29
DK2203170T3 (da) 2012-01-16
PT2203170E (pt) 2011-12-27
JP2010540511A (ja) 2010-12-24
CY1112203T1 (el) 2015-12-09
EP2042179A1 (en) 2009-04-01
EP2203170A1 (en) 2010-07-07
ATE524185T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2014003331A1 (es) Formas cristalinas de un modulador de receptor de androgeno
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
CL2016001895A1 (es) Compuestos
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2011002267A1 (es) Compuesto derivado de pirazolopiridina sustituida, inhibidor de la quinasa lrrk2; procedimiento de preparacion de dicho compuesto; composicion farmaceutica; combinacion farmaceutica; uso del compuesto para prevenir o tratar un trastorno seleccionado de cancer y enfermedades neurodegenerativas.
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
CL2012000163A1 (es) Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras.
BR112012032282A2 (pt) administração transdérmica de memantina
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
DOP2013000236A (es) Inhibidores de la poli(adp-ribosa)polimerasa(parp) para el tratamiento de la neuropatia periferica inducida por quimioterapia (cipn)
CL2007000781A1 (es) Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CL2008003362A1 (es) Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
WO2011116161A3 (en) Arylsulfonamide ccr3 antagonists
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder

Legal Events

Date Code Title Description
FB Suspension of granting procedure